DOCK4, a GTPase Activator, Is Disrupted during Tumorigenesis  by Yajnik, Vijay et al.
Cell, Vol. 112, 673–684, March 7, 2003, Copyright 2003 by Cell Press
DOCK4, a GTPase Activator,
Is Disrupted during Tumorigenesis
coincidence of two different allelic deletions, with the
size of the overlapping homozygous deletion restricted
by the presence of essential genes. In 1993, Lisitsyn
Vijay Yajnik1,2 Charles Paulding,1
Raffaella Sordella,1 Andrea I. McClatchey,1
Mako Saito,1 Doke C.R. Wahrer,1
and Wigler first proposed representational differencePaul Reynolds,1 Daphne W. Bell,1
analysis (RDA) as a screening method for identifyingRobert Lake,1 Sander van den Heuvel,1
homozygous deletions in genomes of tumor cells. TheJeff Settleman,1 and Daniel A. Haber1,*
technique combines subtractive hybridization with dif-1Massachusetts General Hospital Cancer Center
ferential PCR-amplification to isolate DNA fragments2 Gastrointestinal Unit
absent in tumor cells compared with matched normalHarvard Medical School
tissues (Lisitsyn et al., 1993, 1994; Lisitsyn 1995; LisitsynCharlestown, Massachusetts 02129
and Wigler, 1995). The application of RDA to cancer gene
discovery was instrumental in the initial identification of
the BRCA2 and PTEN tumor suppressor genes; both of
which were found to reside within homozygous genomicSummary
deletions in human tumor specimens (Schutte et al.,
1995; Li et al., 1997).We used representational difference analysis to iden-
A limitation to the broad application of RDA in humantify homozygous genomic deletions selected during
cancer gene discovery appears to be the relatively hightumor progression in the mouse NF2 and TP53 tumor
prevalence of silent polymorphic microdeletions in themodel. We describe a deletion targeting DOCK4, a
human genome. Incidental heterozygous germline dele-member of the CDM gene family encoding regulators
tions may become homozygous in tumor specimensof small GTPases. DOCK4 specifically activates Rap
based on their fortuitous location at sites of somaticGTPase, enhancing the formation of adherens junc-
allelic loss (LOH), leading to their isolation in an RDAtions. DOCK4 mutations are present in a subset of
screen (C.P. and D.A.H., unpublished data). To circum-human cancer cell lines; a recurrent missense mutant
vent this problem, we explored the application of RDAidentified in human prostate and ovarian cancers en-
to syngeneic mouse tumor models. We reasoned thatcodes a protein that is defective in Rap1 activation.
the absence of polymorphisms in such mice wouldThe engulfment defect of C. elegans mutants lacking
greatly increase the identification of biologically signifi-the CDM gene ced-5 is rescued by wild-type DOCK4,
cant homozygous deletions, and that genes targetedbut not by the mutant allele. Expression of wild-type,
during cancer progression in mouse models would likelybut not mutant, DOCK4 in mouse osteosarcoma cells
have similar roles in human tumorigenesis (McClatcheywith a deletion of the endogenous gene suppresses
and Jacks, 1998). Following an initiating genetic lesion,growth in soft agar and tumor invasion in vivo. DOCK4
malignant transformation in mouse models follows atherefore encodes a CDM family member that regu-
series of stages that are comparable to those observedlates intercellular junctions and is disrupted during
in human cancers. For instance, in the well characterizedtumorigenesis.
Rip-TAG model, expression of SV40T antigen initiates
a hyperproliferative state which progresses to frank ma-Introduction
lignancy, associated with loss of E cadherin expression,
and induction of insulin-like growth factor 2 and matrixAllelic losses resulting in inactivation of tumor suppres-
metalloproteinases (Hanahan and Weinberg, 2000).
sor genes are thought to contribute to both the initiation
A particularly attractive model in which to study tumor
and progression of human cancer (Cavenee et al., 1983;
progression is the TP53/ NF2/mouse, which repro-
Fearon, 1997). Tumor suppressors implicated in tumor ducibly gives rise to tumors with high metastatic poten-
initiation have been most readily identified by analysis tial and from which established cell lines are readily
of cancer pedigrees, in which inheritance of a mutant generated (McClatchey et al., 1998). The use of tumor
allele segregates with cancer predisposition. To date, cell lines, free of contaminating normal cells, greatly
few genes have been isolated by virtue of their inactiva- enhances the efficiency of genomic subtraction in RDA.
tion during cancer progression. Tumor loss of heterozy- The most common tumor cell types in this mouse model
gosity at polymorphic markers (LOH) typically results are fibrosarcomas and osteosarcomas, virtually all of
from somatic chromosomal deletion or non-disjunction which demonstrate homozygous inactivation of TP53
events that render a cancer cell homozygous for a mu- and NF2 genes, residing on mouse chromosome 11.
tant allele. However, the relatively large size of hemizy- Loss of TP53, the most common genetic event in human
gous allelic losses in cancer cells complicates efficient cancer, leads to genomic instability and may increase
gene discovery strategies; homozygous genomic dele- the likelihood of subsequent genetic alterations includ-
tions are rare, but their smaller size facilitates identifica- ing specific chromosomal deletions (Jain et al., 2001).
tion of the targeted tumor suppressor gene (Dryja et al., NF2, the gene responsible for Neurofibromatosis type
1986; Call et al., 1990; Kamb et al., 1994; Li et al., 1997; II, encodes a member of the Moesin, Ezrin, and Radixin
Steck et al., 1997). Such deletions may result from the (ERM) family of structural proteins and is commonly
mutated in human mesotheliomas (Sekido et al., 1995).
While inactivation of these two genes initiates malignant*Correspondence: haber@helix.mgh.harvard.edu
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proliferation in this mouse tumor model, it is likely that the outside limits of the homozygous deletion. Remark-
ably, this is an extremely “gene-poor” locus, containingadditional genetic events, including homozygous dele-
tions, may contribute to the highly metastatic tumor only one transcription unit identified by gene prediction
programs in both mouse and humans.phenotype.
Here, we identify a gene, DOCK4, targeted by a homo- A single human transcript comprised of 53 exons was
predicted, spanning a 500 kb locus between ZNF277zygous deletion in an osteosarcoma cell line derived
from the TP53-NF2 mouse model. DOCK4 encodes a and NLRR3, with the most 5 exon present in human
BAC AC 003077 and the most 3 exon and untranslatedmember of the CDM gene family, implicated in the regu-
lation of Rac GTPase signaling and defined by its found- region within BAC AC 005047. This putative transcript
was confirmed by analysis of the human EST database,ing members, C. elegans ced-5, vertebrate DOCK180,
and Drosophila Myoblast City (Hasegawa et al., 1996; which revealed several matches from multiple tissue
types. Reverse transcription (RT)-PCR was used to am-Nolan et al. 1998; Wu and Horvitz, 1998). DOCK4 acti-
vates Rap GTPase, regulating the formation of intercel- plify the predicted exons in overlapping fragments, con-
firming their presence within a single transcript. We usedlular adherens junctions. Reconstitution of DOCK4 ex-
pression in mouse osteosarcoma cells with a deletion 5-RACE-PCR to generate multiple clones from a pla-
cental cDNA library, identifying the transcriptional startof the endogenous gene results in reestablishment of
cell-cell junctions and suppression of soft agar colony within an upstream BAC AC 004111.1. The large geno-
mic locus spanned by this gene is in part due to intronformation and tumor invasion in vivo. Transgenic ex-
pression of DOCK4 in C. elegans ced-5 null mutants 1, covering an entire BAC (AC 004001.1). Of note, marker
D7S523, which defines a common site of LOH in humancorrects their defect in the engulfment of apoptotic cell
bodies. A subset of human cancer cell lines harbor muta- prostate cancers, is within this BAC, raising the possibil-
ity that this gene may be a target for allelic losses intions in DOCK4; a Pro1718Leu mutation found in both
prostate and ovarian cancers abrogates Rap1 GTPase human cancers (Takahashi et al., 1995; Koike et al.,
1997). Taken together, these studies allowed assemblyactivation, its correction of the Ced-5 phenotype in C.
elegans, and its tumor suppressor properties in mouse of the full-length coding region for a previously unchar-
acterized gene, encoding a protein of 1966 amino acidsosteosarcoma cells.
with extensive homology to DOCK180, a regulator of
the small GTPase Rac (Hasegawa et al., 1996, BrugneraResults
et al., 2002). In vertebrates, DOCK gene family members
include DOCK180, its lymphocyte-specific homologIsolation of a Homozygous Deletion in 3081
DOCK2 (Nishihara et al., 1999), and an EST sequenceOsteosarcoma Cells
(KIAA0299) initially deposited in the database asWe used RDA to screen sarcomas derived from six
DOCK3. DOCK3 has recently been identified as a pre-TP53/ NF2/ mice for the presence of homozygous
senilin binding protein (Kashiwa et al., 2000) and as adeletions. Genomic DNA from tumor-derived cell lines
“modifier of cell adhesion” (MOCA) in neuronal cellswas PCR-amplified as the “driver” and used in excess
(Chen et al., 2002). We have therefore named the geneto subtract shared sequences from the matched normal
DOCK4. DOCK4 is expressed in multiple tissue types,DNA “tester” (Lisitsyn and Wigler, 1995). Differentially
with highest levels in skeletal muscle, prostate, andamplified genomic sequences were obtained in 3/6 tu-
ovary (Figure 1B).mors, all of which were confirmed as being homozy-
gously deleted by Southern blotting in the tumor cell
line of origin. Fibrosarcoma 3452 was found to have a DOCK4, a CDM Family Member
The overall structure of DOCK4 is highly similar to otherdeletion of the p16INK4a/p19ARF locus, a common site of
chromosomal deletions in both mouse and human can- CDM family members, with an N-terminal SH3 domain,
a region of extended homology from amino acids 100cers. Fibrosarcoma 3872 contained multiple large dele-
tions of the Y chromosome, an observation that is also to 1700 (35% amino acid identity with DOCK180, 39%
with DOCK2, and 54% with DOCK3), and a C-terminalfrequently observed in cancers derived from males (Lis-
itsyn and Wigler, 1995). Osteosarcoma 3081 produced proline-rich region, which appears to be unique to each
family member (Figure 2). The CDM protein family hastwo homozygously deleted genomic fragments, mapped
using radiation hybrid screening near marker D12Mit148 recently been divided into two classes based on se-
quence alignment programs (Meller et al., 2002; Reif andon mouse chromosome 12, a genomic locus that is syn-
tenic to human chromosome 7q31 (Figure 1A). The RDA Cyster, 2002; Cote and Vuori, 2002). Class A includes
mammalian DOCK180 and DOCK2, and Drosophila Myo-products were further mapped to two adjacent bacterial
artificial chromosome (BAC) clones, AC 079370 and AC blast City, while class B includes mammalian DOCK3
and DOCK4, and an unnamed Drosophila protein,079369. While the mouse genomic locus was unordered,
the syntenic human locus was completed and showed CG31048. DOCK class A proteins appear to function as
upstream regulators of Rac GTPase signaling, and theirhighly conserved coding sequences that were used to
define the extent of the murine deletion. Flanking the inactivation is associated with dramatic defects in cell
migration and developmental patterning (Hasegawa ettelomeric side of D12Mit148 is the zinc finger gene,
ZNF277 (Liang et al., 2000), which is not deleted in tumor al., 1996; Nolan et al., 1998; Wu and Horvitz, 1998; Fukui
et al., 2001). The signaling pathway regulated by class3081 (Figure 1A). On the centromeric side, the Neuronal-
specific leucine-rich repeat gene, NLRR3, is also present B proteins has not been defined. Interestingly, only a
single CDM family member, ced-5, exists in C. elegans.in tumor 3081. These two genes are separated by 900
kb in the human genomic sequence and hence define ced-5 was initially identified by its role in both the en-
GTPases Regulator DOCK4 Disrupted in Tumorigenesis
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Figure 1. Identification of DOCK4 within a Homozygous Genomic Deletion in Osteosarcoma 3081
(A) Schematic representation of the homozygous deletion on mouse chromosome 12 containing RDA products clone 11 and clone 13. This
region is a representation of the linear sequence of mouse chromosome 12 from Ensembl database (nucleotides 12.345  105 to 12.354 
106 ). Southern blot hybridization of these deleted RDA products, as well as markers from the flanking non-deleted genes ZNF277 and NLRR3,
are shown for tumor 3081 and two unrelated controls 3442 and 3978. The gene targeted by the deletion, termed DOCK4, is comprised of 53
exons, spanning 500 kb of genomic DNA (Ensembl database 12.346  105 to 12.351  106 ). No other identifiable transcription unit is present
between ZNF277 and NLRR3 in either mouse or human sequence. Human marker D7S523, frequently targeted by allelic loss affecting
chromosome 7q31 in human cancers, maps to the first intron of DOCK4.
(B) Northern blot demonstrating expression of the 8.5 kb DOCK4 transcript in multiple human tissues: lanes 1, heart; 2, brain; 3, placenta; 4,
lung; 5, liver; 6, skeletal muscle; 7, kidney; 8, pancreas; 9, spleen; 10, thymus; 11, prostate; 12, testis; 13, ovary; 14, small intestine; 15, colon;
and 16, peripheral blood leukocytes. GAPDH, loading control.
gulfment of apoptotic cells and the migration of the While Zizimin1 is not a CDM family member, two discrete
domains of 250 and 550 amino acids, respectively, showdistal tip cell of the gonad. These processes require
cytoskeletal reorganization and may involve distinct 20% sequence identity with DOCK180 and have been
termed either the DOCK homology regions (DHR1 andGTPase-dependent signals (Wu and Horvitz, 1998; Red-
dien and Horvitz, 2000). DHR2 or “docker”) or the conserved Zizimin homology
(CZH1 and CZH2) (Cote and Vuori, 2002; Meller et al.,The functional properties of CDM proteins have been
most clearly defined for DOCK180, which is activated 2002). DHR2/CZH2 binds to nucleotide-free GTPase,
while the function of DHR1/CZH1 is unclear. DOCK4by integrin signaling, leading to an interaction between
its C-terminal proline-rich domain and the SH3 domain contains both of these conserved domains, raising the
possibility that it may also be an unconventional nucleo-of the adaptor protein CrkII (Albert et al., 2000). The SH2
domain of CrkII in turn binds to the scaffold protein p130 tide exchange factor (Figure 2). In addition to these do-
mains, two other motifs are present only in DOCK4 andCAS, which is phosphorylated by Src and focal adhesion
kinase (FAK), recruiting the exchange factor Rac-GEF CED-5: a consensus binding site for the SH3 domain of
Src (SSB) and a second C-terminal proline-rich motifand triggering the cytoskeletal changes characteristic
of Rac activation (Kiyokawa et al., 1998a and 1998b; (Figure 2). These motifs raise the possibility that some
functional properties of CED-5, the unique CDM familyGu et al. 2001). The proline-rich C-terminal domain of
DOCK4 may therefore play a similar role in Crk II binding member in C. elegans, may be shared with DOCK4, but
not DOCK180. In summary, analysis of the conservedand GTPase signaling (Figure 2; see below). An alterna-
tive pathway for GTPase activation by DOCK180 has domains of DOCK4 suggests that it may play a role in
the regulation of small GTPases implicated in cellularrecently been uncovered with the observation that it can
bind directly to nucleotide-free Rac and interact with motility, cell adhesion, and invasion.
ELMO to mediate nucleotide exchange, despite lacking
the characteristic Dbl homology domain implicated in DOCK4 Mutations in Human Cancer Cell Lines
Marker D7S523, at chromosomal locus 7q31, demon-guanine nucleotide exchange (Brugnera et al., 2002).
DOCK180 has been called an “unconventional nucleo- strates a high frequency of allelic loss (LOH) in human
breast, ovarian, and prostate cancers, and in gliomastide exchange factor”, along with other proteins such
as the CDC42 activator Zizimin1 (Meller et al., 2002). (Takahashi et al., 1995; Koike et al., 1997). A candidate
Cell
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Figure 2. Schematic Representation of Domains Conserved between DOCK4 and other CDM Family Members and Targeted by Mutations in
Human Cancers
Alignment of DOCK4 and the founding members of the CDM protein family: C. elegans CED-5, mammalian DOCK180, and Drosophila Myoblast
City (MBC). All four proteins share an N-terminal SH3 domain. The CDM domain of extended homology between amino acids 100 to 1700 in
DOCK4 contains the Lys1059Thr mutation, a residue conserved in all four family members. Within the C-terminal proline-rich domain shared
by all CDM family members are three conserved regions: C-terminal motif-1, shared only by DOCK4 and CED-5, is disrupted by the Pro1718Leu
mutation; a highly conserved consensus binding site for the SH3 domain of Src is also shared only by DOCK4 and CED-5; and C-terminal
motif-2, shared by DOCK4 and DOCK180, which is targeted by the Val1884Met mutation. DHR1/CZH1 and DHR2/CZH2 domains are present
in unconventional vertebrate GEFs and have been implicated in nucleotide free GTPase binding.
tumor suppressor, ST7, has been identified at that locus, other missense change, Val1884Met, is encoded by a
heterozygous mutation in two independent glioma cellbut recent studies have not supported the initial report of
frequent intragenic mutations, indicating that additional lines and maps to another conserved domain shared
with DOCK180 (C-terminal motif-2; Figure 2). A thirdtumor suppressor genes are likely to reside at this locus
(Zenklusen et al., 2001; Thomas et al., 2001). As an initial heterozygous mutation present in a colorectal cancer
cell line, encoding Lys1059Thr, affects a residue withinscreen for DOCK4 mutations in human tumors, we se-
quenced the 6 kb coding sequence from 44 cancer cell the extended homology domain that is conserved in all
CDM family members (Figure 2). We selected Pro1718-lines, representing a broad range of tumor types. RT-
PCR products were subjected to direct sequencing, and Leu as a human cancer-derived mutation in DOCK4 and
compared its functional properties with those of theany sequence variants identified by cDNA analysis were
confirmed by amplification of genomic DNA. DNA speci- wild-type protein.
mens from 200 healthy individuals (400 chromosomes)
were used to exclude polymorphisms that might be Rescue of the Engulfment Defect in C. elegans
ced-5 Mutants by Wild-Typepresent in the population. Analysis of the DOCK4 coding
sequence revealed five missense changes that were but Not Mutant DOCK4
The high degree of evolutionary conservation in CDMabsent in controls (Table 1). Among these, Pro1718Leu
was found as a homozygous mutation in two indepen- proteins made it possible to use a well-characterized
functional assay in C. elegans to test the properties ofdent cell lines, one derived from ovarian cancer and
the other from prostate cancer. The targeted proline DOCK4 and the tumor-associated mutant Pro1718Leu.
While distinct CDM proteins may mediate activation ofresidue, within the C-terminal proline-rich domain, is
conserved in CED-5 (C-terminal motif-1; Figure 2). An- different GTPases in vertebrates, in C. elegans these
Table 1. hDOCK4 Mutations in Human Cancer Cell Lines
Cancer Cell Line Nucleotide Change and Position Effect on Protein Allele Frequency
OV1063 (Ovarian) C to T at nt 5153 (Homozygous) Missense (Pro1718Leu) 0/380
DU145 (Prostate) G to A at nt 5650 (Heterozygous) Missense (Val1884Met) 0/374
U251 (CNS) C to T at nt 260 (Heterozygous) Missense (THr87Ile) 0/380
SNB19 (CNS) A to C at nt 3176 (Heterozygous) Missense (Lys1059Thr) 0/374
HCT15 (Colorectal) T to C at nt 5263 (Heterozygous) Missense (Ser1755Pro) 0/380
Polymorphisms
C to G at nt 5197 Missense (Pro1733Ala) 2/268
C to T at nt 5777 Missense (Ser1926Leu) 4/126
C to T at nt 5750 Missense (Pro1917Leu) 2/126
G to A at nt 5740 Missense (Val1914Ile) 8/88
G to C at nt 1816 Missense (Glu606Gln) 7/76
GTPases Regulator DOCK4 Disrupted in Tumorigenesis
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Activation of Rap GTPase by DOCK4
We generated CMV-driven, flag-tagged expression con-
structs encoding wild-type DOCK4 or the Pro1718Leu
mutant. Transient transfection into 293T cells confirmed
expression of the predicted 225 kDa protein, while ex-
pression in Caco-2 cells clearly demonstrated localiza-
tion to the cell membrane (Figures 4A and 4B). We there-
fore tested the functional properties of wild-type DOCK4
without the need for membrane targeting using a syn-
thetic CAAX box (Hasegawa et al., 1996). Given the ho-
mology between the proline-rich C-terminal domains of
DOCK4 and DOCK180, we first tested whether DOCK4
also interacts with the N-terminal SH3 domain of the
adaptor protein CrkII. Indeed, transfected DOCK4 pro-
tein is readily coprecipitated from 293T cell lysates with
the GST fused N-terminal SH3 domain of CrkII, whereas
no binding is observed with other SH3 domains, includ-
ing the C terminus of Crk II or the SH3 domain of Abl
(Figure 4B). Of note, the Pro1718Leu DOCK4 mutant
demonstrates significantly reduced binding to CrkII (6
lysate was used to demonstrate reduced binding by the
mutant protein). While the mutation does not directlyFigure 3. Rescue of Apoptotic Body Engulfment Defect in ced-5
affect the binding site for CrkII, we presume that lossMutants by Expression of Wild-Type but not Mutant DOCK4
of the conserved proline residue leads to altered proteinNomarski photomicrographs showing the reflexed region of (A) wild-
folding.type adult gonad, and (B) the same loop region in a ced-5(n1812)
mutant. Arrows indicate multiple cell corpses. The association between DOCK4 and CrkII is consis-
(C) Expression of heat shock-driven ced-5 or DOCK4 rescued the tent with its function within a signaling complex analo-
cell corpse engulfment defect in the germline of ced-5(n1812) mu- gous to that of DOCK180. The DOCK180 protein com-
tants. The number of cell corpses observed within a single morpho- plex has been implicated in Rac signaling, and we
logically normal gonad arm were counted in heat-shocked trans-
therefore screened a panel of small GTPases to identifygenic animals. Animals expressing Pro1718Leu-DOCK4 or a control
the most relevant physiological target for DOCK4. 293Ttransgene (GFP) did not show rescue. The DTC migration defect
of ced-5(n1812) mutants was corrected by ced-5 but not DOCK4 cells were transiently transfected with constructs en-
expression. The percent of animals displaying a migration defect of coding either DOCK4 or the Pro1718Leu mutation, along
either DTC was determined in adult transgenic animals. with tagged constructs encoding either Rac, Rho,
CDC42, or Rap. Cellular lysates were quantified for GTP
bound forms by binding to affinity matrices, followed by
properties are encoded by a single gene, ced-5. Inacti- Western blotting using antibody against the transfected
vation of ced-5 is associated with two primary defects: GTPases. Dramatic activation of Rap GTPase ( 5-fold)
failure of neighboring cells to engulf apoptotic cells lead- is evident in cells transfected with wild-type DOCK4,
ing to the persistence of cell corpses and abnormal but not the Pro1718Leu mutant (Figures 4C and 4D). For
migration of the gonadal distal tip cells (DTCs) (Wu and comparison, 293T cells were also transfected with either
Horvitz, 1998). In a dramatic illustration of the conserva- wild-type Rap or the constitutively active form, Rap63E
tion of this signaling pathway, expression of a heat (Figure 4D). Transient expression of DOCK4 had no ef-
shock-driven DOCK180 construct has been shown to fect on other GTPases, including Rho, Rac, and CDC42
rescue the DTC migration defect in ced-5 mutants (Wu (Figure 4C). Remarkably however, the Pro1718Leu mu-
and Horvitz, 1998). However, the mechanism underlying tant of DOCK4 shows significant activation of both Rac
engulfment of apoptotic corpses has not been defined. and CDC42. This tumor-associated mutation, therefore
exhibits both loss-of-function as well as gain-of-functionWe therefore tested whether heat shock-driven expres-
properties with respect to the activation different smallsion of DOCK4 could rescue this component of the
GTPases. Given the failure of Pro1718Leu-DOCK4 toCed-5 phenotype. Remarkably, expression of wild-type
bind CrkII (Figure 4B), its ability to activate Rac andDOCK4 in C. elegans corrects the engulfment defect in
CDC42-GTPases may result from its association withced-5 mutants, while expression of Pro1718Leu-DOCK4
another adaptor protein, from altered interactions in-has no effect (Figure 3). This rescue was most readily
volving its DHR/CZH domains, or from indirect effectsdemonstrated in the germline, while apoptotic corpses
on small GTPase pathways.in somatic lineages were less affected by ectopic
DOCK4 expression (Figure 3 and data not shown). Ex-
pression of DOCK4 has no effect on DTC migration. Restoration of Adherens Junctions
Taken together with the results of Wu and Horvitz (1998), by DOCK4 and Rap1
our results suggest that DOCK4 and DOCK180 together The original isolation of DOCK4 from a mouse osteosar-
reconstitute the functional properties of CED-5. More- coma cell line with a deletion of the endogenous gene
over, the different results obtained with wild-type and made it possible to test the effects of reconstituting
Pro1718Leu mutant forms of DOCK4 indicate that the its expression in these cells. We therefore generated
multiple cell lines stably expressing DOCK4 or Pro1718-missense mutation indeed affects protein function.
Cell
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Figure 4. Activation of Rap GTPase by DOCK4
Expression of constructs encoding either wild-type DOCK4 or the Pro1718Leu mutation in transient (A–D) and stable (E–F) transfection assays.
(A) Cell surface localization of epitope-tagged DOCK4 following transfection into Caco-2 cells.
(B) Binding of wild-type DOCK4 to the N-terminal SH3 domain of CrkII (GST-Crk N), but not to the C-terminal SH3 domain of CrkII (GST-Crk
C) or to the SH3 domain of Abl (GST-Abl SH3). The Pro1718Leu mutant exhibits reduced binding to GST-Crk N, which is only evident with
addition of 6  cellular lysate. Comparable expression of wild-type and mutant DOCK4 constructs is shown by Western blotting (lysate),
along with equivalent expression of the bacterially synthesized GST-SH3 domains.
(C) Activation of small GTPases following transient transfection of wild-type DOCK4 and the Pro1718Leu mutant into 293T cells. These
expression plasmids were cotransfected along with constructs encoding Rap, HA-Rac, HA-CDC42 or HA-Rho, and active GTP bound forms
were isolated from cellular lysates by incubation with appropriate GST-RBD constructs, followed by Western blotting using antibody to either
Rap or the HA epitope tag (GTP bound). Western blotting of cellular lysates (total) shows comparable expression of the small GTPases.
Activation of Rap GTPase is observed with expression of wild-type DOCK4, but not Pro1718Leu-DOCK4. In contrast, expression of Pro1718Leu-
DOCK4, but not wild-type DOCK4, is associated with activation of Rac and CDC42. Rho GTP levels are unaffected by either variants of
DOCK4.
(D) Quantitative analysis of Rap activation by wild-type DOCK4, compared with the Pro1718Leu mutant. For comparison, Rap GTPase levels
are shown for cells transiently transfected with either wild-type Rap or the constitutively active mutant Rap63E.
(E) Western blot analysis demonstrating expression of epitope-tagged DOCK4 or the Pro1718Leu mutant in two independent, stably transfected
clones derived from 3081 mouse osteosarcoma cells with a homozygous deletion of the endogenous gene.
(F) Phalloidin staining to demonstrate cellular actin patterns of 3081 cells stably reconstituted with either wild-type DOCK4 or the Pro1718Leu
mutant. Compared with vector-transfected cells, DOCK4 expressing cells have increased actin stress fibers, while cells expressing the
Pro1718Leu mutant demonstrate presence of filopodia, a characteristic of CDC42 activation. All cells were in mid log phase of growth.
Leu-DOCK4 in 3081 osteosarcoma cells (Figure 4E). For such intercellular contact points has been linked with
cancer progression (Christofori and Semb, 1999; Hajraall subsequent experiments, multiple cell lines were
used to ensure against the effects of clonal selection. and Fearon, 2002). We therefore tested 3081 parental
cells and their reconstituted derivatives for expressionThe morphology of cells expressing these constructs
differs remarkably: compared with parental 3081 cells, of -catenin, a marker for adherens junctions. Osteosar-
coma cell line 3081 cells do not display contact inhibitionthose expressing wild-type DOCK4 have a flattened
morphology and prominent actin stress fibers, while and fail to form adherens junctions, as demonstrated
by a diffuse staining pattern for -catenin (Figure 5A).those transfected with Pro1718Leu-DOCK4 have filo-
podia, a structural characteristic of CDC42 activation In marked contrast, 3081 cells expressing wild-type
DOCK4 grow to a lower cell density at confluence (Figure(Figure 4F).
While Rap1 was initially identified as a Ras antagonist 6A), demonstrating marked contact inhibition. -catenin
staining shows characteristic localization to discrete re-thought to sequester Ras effectors within an inactive
complex, more recent data have raised the possibility gions of the membrane representing adherens junctions
(Figure 5B). No such effect is seen in 3081 cells express-that Rap may itself mediate distinct signaling pathways
(Bos et al., 2001). In the developing Drosophila embryo, ing Pro1718Leu-DOCK4 (Figure 5C).
To test whether Rap GTPase activation is requiredRap1 plays an important role in formation of cell-cell
adherens junctions (Knox and Brown, 2002). Loss of for the restoration of adherens junctions by wild-type
GTPases Regulator DOCK4 Disrupted in Tumorigenesis
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Figure 5. Regulation of Cellular Adherens
Junctions by Expression of DOCK4 and Rap
GTPase
Staining of confluent cells 3081 osteosar-
coma cells (A–E) and primary mouse osteo-
blasts (G–I), using antibody to -catenin, a
constituent of cellular adherens junctions.
(A) Adherens junctions are not visualized in
the parental DOCK4 null 3081 osteosarcoma
cells.
(B) Reconstitution of wild-type DOCK4 ex-
pression in these cells is associated with ap-
pearance of intercellular adherens junctions.
(C) No such effect is seen in 3081 cells ex-
pressing the Pro1718Leu-DOCK4 mutation.
(D) Coexpression of a dominant-negative
variant, RapN17, abrogates the induction of
adherens junctions by wild-type DOCK4 in
3081 cells.
(E) Transfection of parental 3081 cells with
the constitutively active Rap variant, Rap63E,
is sufficient to restore formation of adherens
junctions.
(F) siRNA to the DOCK4 mRNA is effective
in suppressing the endogenous transcript in
primary mouse osteoblasts, as demonstrated
by RT-PCR (35 cycles). No effect is seen with
a nonspecific siRNA (targeting NY-REN-60
mRNA), and an irrelevant transcript (p16) is
unaffected by siRNA treatment.
(G) Normal primary mouse osteoblasts dem-
onstrate presence of adherens junctions.
(H) Treatment of primary osteoblasts with siRNA targeting endogenous DOCK4 for 48 hr leads to a reduction in cellular adherens junction
formation.
(I) siRNA targeting the nonspecific gene has no effect on adherens junctions.
DOCK4, 3081 cells expressing wild-type DOCK4 were definitive cadherens junctions (Figure 5G). Treatment of
cells with DOCK4 siRNAi for 48 hr effectively reducesstably cotransfected with a dominant-negative Rap1
construct (RapN17). Disruption of Rap1 signaling in mul- the levels of endogenous DOCK4 mRNA to 5% of
baseline (Figure 5F). Remarkably, this treatment is asso-tiple clones abrogated the effect of DOCK4 on -catenin
expression (Figure 5D). To determine if activation of Rap ciated with marked suppression of adherens junctions
(Figure 5H). No such effect was observed in primaryitself is sufficient to enhance formation of adherens junc-
tions in parental 3081 cells, these cells were transfected osteoblasts treated with control oligonucleotides (Fig-
ure 5I). The effect of DOCK4 on cell junctions thereforewith a constitutively active variant of Rap1, Rap63E. In
multiple stable cell lines, expression of Rap63E in the appears to be independent of NF2 function.
absence of DOCK4 was sufficient to induce the forma-
tion of adherens junctions (Figure 5E). Thus, reconstitu- Tumor Suppressor Properties of DOCK4
To explore the physiological significance of DOCK4-tion of DOCK4 expression in 3081 cells appears to re-
store cell-cell contacts through its activation of Rap mediated signaling, we examined the growth properties
of 3081 osteosarcoma cells expressing either wild-typeGTPase. We note that the low levels of endogenous
Rap1 in 3081 cells prevented direct measurement of or Pro718Leu-DOCK4. The restoration of contact inhibi-
tion in 3081 cells expressing wild-type DOCK4 was asso-altered Rap-GTP levels in cells reconstituted with wild-
type DOCK4. However, the potent activation of Rap1 by ciated with a reduction in maximal cell density, without
affecting generation time in culture (Figure 6A). Colonytransient transfection of DOCK4 in 293T cells (Figure
4C), coupled with the effect of Rap mutants in stably formation in soft agar, an in vitro correlate of tumorigene-
sis was markedly reduced for DOCK4-reconstitutedtransfected 3081 cells (Figures 5D and 5E), suggest that
the effect of DOCK4 is likely to be mediated through 3081 cells, whereas expression of Pro1718Leu-DOCK4
had little effect (Figure 6B). To further examine the po-Rap-GTP signaling.
In addition to lacking DOCK4 expression, 3081 cells tential tumor suppressor effect of wild-type DOCK4, re-
constituted 3081 cells were inoculated subcutaneouslyare null for TP53 and NF2. NF2 itself encodes a cytoskel-
eton-associated protein implicated in GTPase signaling into nude mice. At three weeks, large tumors ( 2 cm
diameter) were evident in 4/4 mice injected with vector-(Shaw et al., 2001), raising the possibility that the effects
of DOCK4 in these cells may depend on the absence transfected 3081 cells (Figure 6C). Histological analysis
showed frank invasion of subcutaneous tissue, fat, andof functional NF2. To address this possibility, we used
siRNA to reduce DOCK4 expression in normal mouse muscle (Figure 6D). In contrast, 3081 cells expressing
wild-type DOCK4 produced much smaller nodules atosteoblasts. These primary cells comprise the pre-
sumed cell of origin of osteosarcomas and demonstrate the site of injection (3–4 mm diameter) in 4/4 mice. Histo-
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Figure 6. Suppression of Tumorigenicity by Wild-Type DOCK4, but not Pro1718Leu-DOCK4
Neoplastic properties of 3081 cell lines stably reconstituted with either wild-type or mutant DOCK4. For each construct, two independent cell
lines were tested in multiple experiments.
(A) Quantitation of viable cells following seeding onto plastic substrate. The doubling rate of all cell lines is comparable, but the final confluent
cell density of cells expressing wild-type DOCK4 is considerably reduced. At each time point, standard deviation was within 10% of average
cell numbers.
(B) Anchorage-independent growth of 3081 cells expressing vector, wild-type DOCK4 or the Pro1718Leu-DOCK4 mutation, following plating
in soft agar.
(C) Tumor formation by reconstituted 3081 osteosarcoma cells, following subcutaneous inoculation into nude mice. For each construct, two
independent stably transfected cell lines were tested in duplicate. All injected cell lines gave rise to tumors, but the size of those expressing
wild-type DOCK4 was considerably reduced.
(D) Hematoxylin and eosin-stained sections of 3081 tumors arising in nude mice (2.5 and 10 magnification). Vector- and Pro1718Leu-
DOCK4-expressing cells give rise to very large and invasive tumors, while DOCK4-expressing cells produce small circumscribed tumors.
Tumor cells (T) are shown invading surrounding subcutaneous fat (F), as well as metastatic to lymph node (LN). Invasion of surrounding muscle
(M) is also evident in Pro1718Leu-DOCK4 expressing tumors. In contrast, DOCK4-reconstituted 3081 cells give rise to noninvasive tumors
with well-demarcated margins (black arrows).
logically, these tumors appeared well-circumscribed cell migration. In contrast, DOCK4 modulates signaling
and pseudo-encapsulated, and they failed to show any through the Rap GTPase, enhancing the formation of
invasion of surrounding tissues (Figures 6C and 6D). cellular adherens junctions. We show that reconstitution
Osteosarcoma cell line 3081 cells expressing Pro1718- of DOCK4 expression in mouse osteosarcoma cells with
Leu-DOCK4 produced large invasive tumors, compara- a deletion of the endogenous gene restores the forma-
ble to the parental DOCK4 null cell lines. These data tion of adherens junctions, an effect that is suppressed
suggest that mutations of DOCK4 in human cancer cells by coexpression of a dominant-negative Rap construct.
may be associated with loss of cell junctions and a more Expression of constitutively active Rap1 in these cells
invasive phenotype. is sufficient to restore adherens junctions, supporting
the link between Rap signaling and formation of intercel-
lular contacts, which has previously been documentedDiscussion
in Drosophila (Knox and Brown, 2002). These functional
properties of DOCK4 are not restricted to cells derivedWe have used RDA to screen a mouse tumor model for
from p53- and NF2-driven mouse tumor models, sincehomozygous genomic deletions, leading to the isolation
treatment of normal mouse osteoblasts with siRNA tar-of DOCK4, a gene that is also targeted by intragenic
geting DOCK4 also demonstrates a reduction in ad-mutations in human prostate, ovarian, and potentially
herens junctions. Consistent with the importance ofother cancers. DOCK4 encodes a member of the CDM
these intercellular contacts in suppressing tumorigenic-gene family, characterized by their activation of Rac
GTPase and their essential roles in morphogenesis and ity, DOCK4-reconstituted mouse osteosarcoma cells
GTPases Regulator DOCK4 Disrupted in Tumorigenesis
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show contact inhibition, suppression of growth in soft lian cells and suggests that DOCK4 functions, at least
in part, by maintaining active Rap signaling.agar, and a reduction in tumor invasiveness in vivo.
Intercellular adherens junctions are formed by homo-Finally, we show that ectopic expression of DOCK4 in
philic interactions between the extracellular domains ofC. elegans ced-5 mutants rescues their defect in en-
E-cadherin, linked by their intracellular tail to cateninsgulfment of apoptotic bodies, pointing to a highly con-
and to the actin cytoskeleton (Jamora and Fuchs, 2002).served evolutionary pathway that mediates intercellular
AF6, a PDZ domain-containing protein present in thecontact. Taken together, these studies illustrate a gen-
adherens junction, binds to both Rap and the actin cy-eral strategy using mouse tumor models to identify
toskeleton, and may enhance the link between structuralgenes inactivated during tumor progression and point
components of the adherens junction and small GTPaseto a potentially important role for Rap signaling in sup-
signaling (Boettner et al., 2000). Several lines of evidencepressing human cancer.
support the role of adherens junctions in the invasiveThe CDM gene family encodes proteins that are criti-
properties of cancer cells (Perl et al., 1998; Perego etcal integrators of extracellular signals leading to small
al. 2002). Germline mutations in E-cadherin underlie aGTPase activation. DOCK180, for instance, is recruited
subset of familial gastric cancer with a particularly inva-to the cell membrane and activated following integrin
sive phenotype (Guilford et al., 1998). Somatic loss ofsignaling, leading to formation of a complex including
E-cadherin expression, either through mutations or pro-the adaptor protein CrkII, the scaffold protein P130CAS
moter methylation, has been linked to progression of(Kiyokawa et al., 1998a, 1998b). DOCK2, a CDM family
tumorigenesis, with restoration of expression leading tomember whose expression is restricted to lymphocytes,
tumor suppression (Christofori and Semb, 1999). An-also appears to regulate Rac signaling and modulate
other component of the adherens junction, -catenin,cellular migration (Fukui et al., 2001). Both DOCK180
serves as a useful histological marker for adherens junc-and DOCK2 share extensive homology with DOCK4, al-
tions. While it is frequently mutated in human cancer,though they diverge at the C-terminal 250 amino acids,
these mutations are thought to function directly in thea domain that may mediate binding to distinct adaptor
wnt signaling pathway, rather than mediating alterationsproteins and lead to the activation of different subsets
in adherens junctions. To date, unlike Ras, mutationsof small GTPases. The high degree of evolutionary con-
have not been reported in Rap1. Altered expression ofservation of CDM family members also provides impor-
the GTPase RhoC has recently been linked to metastasistant insight into their respective functions. Only one fam-
in a melanoma model (Clark et al., 2000). Taken together,ily member, ced-5, is present in C. elegans, and its loss
mutational and functional studies suggest that loss ofof function involves apparent defects in both cellular
adherens junction components are likely to contributemigration (distal tip cell migration) and intercellular ad-
to invasive properties of tumor cells. Support for thehesion (engulfment of apoptotic corpses by neighboring
role of small GTPases in this process is derived fromcells). Remarkably, CED-5 and DOCK4 share a C-ter-
the presence of DOCK4 mutations in human cancers.minal domain that is absent in DOCK180 and DOCK2,
Analysis of human cancer cell lines identified five dis-including a conserved proline residue that is targeted
tinct missense mutations in DOCK4 that were not detect-by the Pro1718Leu mutation, leading to loss of CrkII
able in nearly 400 control chromosomes. Of particularbinding and Rap activation. Based on its sequence con-
interest is the Pro1718Leu mutation that was detectedservation, CED-5 may therefore integrate signaling path-
in both a prostate and an ovarian cancer cell line. Theways, which in vertebrates, are regulated by distinct
fact that this mutation arose independently in two can-CDM genes.
cer cell lines raises the possibility of a specific gain-of-Rap was first identified in a screen for suppressors
function mechanism. Similarly, two independent brainof K-Ras-mediated cellular transformation (Kitayama et
tumors were found to have the Val1884Met mutation,al., 1989). Given the close homology between the ef-
which we have not characterized in detail. Functional
fector binding domains of Ras and Rap, its apparent
analysis of Pro1718Leu-DOCK4 demonstrated failure of
tumor suppressor properties were initially postulated
the mutant protein to bind to CrkII, activate Rap GTPase
to result from the sequestration of Raf and other Ras signaling, restore cellular adherens junctions in 3081 cells,
effectors within an inactive complex (Vossler et al., 1997; or affect their contact inhibition, soft agar colony forma-
Bos et al. 2001). However, more recent studies have tion, or in vivo invasiveness. While this tumor-derived
suggested that Rap may in fact mediate a distinct cellu- mutation thus appears to be non-functional in these
lar signaling pathway. In Drosophila, a gain-of-function assays, it is of interest that expression of Pro1718Leu-
mutation in Rap leads to the “roughened” phenotype, DOCK4 activates CDC42 and Rac GTPase activity, prop-
which is not affected by altered expression of Ras (Hari- erties that are not observed with the wild-type protein.
haran et al., 1991). Similarly, Rap loss-of-function muta- The physiological significance of this effect is supported
tions in flies lead to severe morphogenesis defects that by the observation of characteristic CDC42-associated
are not modulated by Ras (Asha et al., 1999). Specific filopodia in cells expressing ectopic Pro1718Leu-
Rap effectors have not been identified, but a potential DOCK4. Activation of CDC42 and Rac GTPases may be
link to the regulation of intercellular contact has been a direct property of the mutant protein or, alternatively,
suggested by observations on Drosophila Rap1 null may be the indirect result of dysfunctional protein inter-
cells, which demonstrate loss of circumferential ad- actions affecting interconnected GTPase signaling
herens junctions (Knox and Brown, 2002). Our observa- pathways. The observation that Pro1718Leu-DOCK4
tions linking Rap activation to adherens junctions in shows reduced binding to the adaptor protein CrkII ar-
both mouse osteosarcoma cells and in normal mouse gues against direct activation of these GTPases through
this protein complex. However, DOCK4 may also medi-osteoblasts supports this effector pathway in mamma-
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database and corresponds to a 900 kb segment (nucleotidesate direct GEF activity through the DHR/CZH domains,
12.345  105 to 12.354  106 in the Ensembl database).which are unaltered by the Pro1718Leu mutation. While
further work will be required to demonstrate whether
Mutational Analysis of DOCK4 in Human Cancer-Derivedthis mutant truly exerts gain-of-function properties, it is
Cell Linesof interest that CDC42 and Rac activities have been
The entire coding region of DOCK4 was amplified by RT-PCR from
linked with increased cellular migration and may thus a panel of 44 sporadic cancer cell lines representing a variety of
enhance the invasive phenotype (Keely et al., 1997; tumor types. Cell lines analyzed were derived from tumors of the
breast (MCF7ADR, MDAMB435, T47D, BT483, MDAMB436,Schmitz et al., 2000).
MDAMB468, MDAMB415, MDAMB231, MDAMB157, HS467T,Finally, the successful application of RDA to mouse
HS496T, UACC893, and BT549), ovary (ES-2, IGROV-1, MDAH2774,tumor models provides a general strategy for identifying
OV1063, OVCAR3, OVCAR4, OVCAR5, OVCAR8, SKOV3, andgenes that are targeted by chromosomal deletions, fol-
SW626), lung (NCIH460, NCIH522, and HOP92), CNS (SF295, SNB19,
lowing the initiating genetic lesions that define each and U251), colon (COLO205, HCT116, HCT15, and HT29 SW620),
model. The use of syngeneic mouse tumor models cir- kidney (ACHN, CAKI-1, and U031), and prostate (DU145 and PC3),
in addition to melanomas (LOXMVII, SKMEL2, UACC62) and osteo-cumvents a major problem of RDA, namely the isolation
sarcomas (U20S and SAOS2). A control population was providedof silent polymorphic deletions in the human population
by EBV-immortalized lymphoblastoid cell lines established from 200that are rendered homozygous in tumor cells by virtue
healthy blood donors. Total cellular RNA was extracted using RNA-of their presence within a common region of LOH. While
STAT60 (Teltest, Friendswood, Texas) according to the manufactur-
technically challenging, RDA offers the advantage of a er’s instructions. The DOCK4 coding region was amplified in a series
genome-wide screen for homozygous deletions, which of 13 overlapping fragments (A–M) using the following primer combi-
nations which are listed in the 5-3 orientation: fragment A (AAGGGare typically considerably smaller than regions of hemi-
GCGCGGGGATTACAAAGCC and TGGGGCAATGAACAACTGGGAzygous allelic loss measured by traditional LOH map-
CTG); fragment B (TGGGGCAATGAACAACTGGGACTG and CTGping. High throughput approaches to identifying ge-
CACAGCCAAAGGGTCGTCGGTACTGG); fragment C (CTGAATAnomic deletions, such as array-based comparative
GAAACGGGCTTCCCAAA GC and GGTACTCACTGGCTGGTGGCT
genome hybridization (CGH) will greatly enhance this CCCC); fragment D (CTATTGAAAGGGGA GAATTTGAGAAAG and
strategy, once the increased density of arrayed markers CGAGAAACTTTACTATCTCTGAG); fragment E (GAAATG GAGAAC
CCACCCAGACAAG and GTGATGTAACACGACAGGCAGAA); frag-allows for high resolution deletion mapping (Hodgson
ment F (CTGAGCTCTTTCCCTGCCGTGTAC and CATCTCCGGGCet al., 2001). Together with the completion of the mouse
GTATCAATATTCGG); fragment G (ACAGATAGACATTATCAACAGgenomic sequence, the increasing number of physiolog-
CTTC and CTGTTTAAAGTTGCCACT CCGCCTC); fragment H (CAGically relevant mouse tumor models makes this ap-
CCAGATCTTCGGAATGTCATG and GTCATGCCCT CGACACACAA
proach attractive to identify genes whose inactivation ACTC); fragment I (CCGGAAGATTGCAGAGCAGTATGAG and AAT
may be relevant to human cancer. CAGAGTCTTCAGGTGCTGATTC); fragment J (AGAGTCTCTGGGT
GGAGA GAACGTC and CAAACTTCTCATGCACGGCCAAACC);
fragment K (CAGGTATC A AGAGGCATTCTTTGTC and GATTAAAExperimental Procedures
CAGCATCCTCTGCGAAGGC); fragment L (CTCAAGCTTGAGTTCT
ACTCACTCG and CCTCCCCGCCGTAGCTCGGCACGGG); andRepresentational Difference Analysis (RDA)
fragment M (CAACTCCCCTGTCTTGTCGGGCAG and GCATCGand Positional Cloning of DOCK4
CAGGTACATA GAAAAGTGAC. All PCRs were performed at an an-For RDA, genomic DNA from six tumor cell lines derived from NF2/
nealing temperature of 58C with the exception of fragments C, F,TP53 double heterozygous mice (driver) was compared with
and J for which annealing temperatures of 63C, 63C, and 60C werematched normal DNA (tester). Mice used were inbred in the 129/
used, respectively. Uncloned RT-PCR products were sequenced inSv background to reduce polymorphic differences that complicate
both directions using the BigDyeTerminator kit (Applied Biosystems)RDA. Genomic DNA was digested with BglII, ligated to adapters,
and analyzed on the ABI3100 genetic analyzer. Heterozygous posi-and subjected to three rounds of subtractive hybridization and PCR
tions were marked using Factura and displayed using Sequenceamplification as described (Lisitsyn and Wigler, 1995). RDA products
Navigator software. Sequence variants detected at the cDNA levelcomprising differentially amplified PCR products were cloned and
were subsequently confirmed at the genomic DNA level. The allelehybridized to Southern blots containing the initial driver and tester
frequency of each sequence variant was determined by genotypingamplicons, as well as primary genomic DNA from tumor cell lines
the control population.and matched normal mouse tissue. RDA products confirmed to
reside within homozygous deletions in mouse tumor cell lines were
sequenced and mapped using mouse-hamster radiation hybrid pan- Expression Analysis and Transfection Studies
Northern blots of multiple human tissues (Clontech blots H1 andels (Research Genetics) as well as database analysis (NCBI). Posi-
tional cloning of DOCK4 was achieved using RDA clones 11 and 13 H2) were carried out using Express Hybridization buffer (Clontech).
Full-length DOCK4 expression constructs were generated encodingfrom tumor cell line 3081. The RDA products initially mapped to
two unordered genomic bacterial artificial chromosomes (BACs) on the wild-type and Pro1718Leu mutation in plasmid pCDNA3.1, both
with and without an N-terminal flag epitope. All constructs weremouse chromosome 12, BAC AC079369, and BAC AC079370. The
syntenic human genomic sequence on chromosome 7 (BAC confirmed by sequencing analysis. All cells were grown in DMEM
with 10% fetal calf serum, and transient transfection was carriedAC003079 and AC003080) is completed and ordered and was there-
fore used in gene prediction programs. EST matches, RT-PCR, and out using the lipid-based reagent, Fugene (Roche). Stable cell lines
were prepared by cotransfecting DOCK4 expression constructs with5-RACE (placental library) were used to confirm predicted coding
and untranslated sequences. The transcriptional start and the first the selection plasmid pBABE puro, followed by selection using 3
ug/ml puromycin. RapN17 and Rap63E expression plasmids wereexon of DOCK4 resides within BAC AC004111.1; a large intron 1
spans the entire BAC AC004001.1; with the second exon and re- cotransfected with plasmid pcDNA4/TO-E (Invitrogen), followed by
selection using 100 ug/ml zeocin. Expression of stably transfectedmaining coding sequence spanning BAC AC003080, BAC
AC003079, and BAC AC005047. The following primers were used constructs was confirmed by Western or Northern blot analysis, and
multiple cell lines were tested to ensure against the effects of clonalto amplify genomic fragments specific for ZnF277 (AGGTTCCTTGG
TGGCAACGATGTGG and AGTTCTGTCGCAGTATGGCTGTGGC) selection. Primary mouse osteoblasts were isolated as described
(Thomas et al., 1996). RNAi studies were done as described in El-and NLRR3 (ACCCTGCTCTCTACC ATTTCTCCCGGAGAA and
TGCCGTGGTAGAGGGCACTGAGGGCGTTGG). Mouse sequence bashir et al. (2001). SiRNA for DOCK4 was designed to target nucleo-
tides GUGCGACGGCUGGUACAGA, corresponding to N19 after thefor this segment of chromosome 12 is also available in the Ensembl
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two A residues at nucleotides 104 and 105 of DOCK4 transcript. Received: September 24, 2002
Revised: January 29, 2003Transfections were done with oligofectamine (Invitrogen) as per
manufacturer’s instructions. Cells were either fixed for immunofluo-
rescence or harvested for RNA isolation, 48 hr after transfection. References
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